Approved clinical approval of kazinan 1.1 new drug CM082
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The processing status of CM082 (cxhl1301192), a class 1.1 new drug of kananji Pharmaceutical Technology (Shanghai), was changed to "CFDA approval" on December 19, 2014, and clinical approval documents will be obtained soon Previously, kazinan had obtained the approval of CM082 capsule in April 2012, and this time it was the tablet of CM082 CM082 is an anti-tumor drug of tyrosine kinase inhibitor Its research and development goal is to retain the efficacy of Pfizer sunitinib and significantly reduce the toxicity The project is invested by Shanghai Zhangjiang science and Technology Venture Capital Co., Ltd in kananji, and incubated by VC + IP + CrO (venture capital + intellectual property + R & D outsourcing service) Vic mode Another class 1.1 Anti-tumor New Drug Project CM118 (cxhl1400725) of kananji is also invested by Zhangjiang Branch and adopted Vic mode, which is still under review.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
